Adenocarcinoma of the Rectum Clinical Trial
Official title:
Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma
Phase I trial to study the effectiveness of radiation therapy plus chemotherapy followed by surgery and additional chemotherapy in treating patients who have advanced nonmetastatic primary cancer of the rectum. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may be an effective treatment for rectal cancer
PRIMARY OBJECTIVES:
I. To identify maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of
oxaliplatin when combined preoperatively with concurrent radiation therapy (XRT) and
fluorouracil (5-FU) by PVI.
II. To evaluate the resection rate for T4 rectal cancers, the pathologic CR rate for T3 and
T4 rectal cancers, and the expected versus actual type of resection (APR vs. LAR vs.
LAR/coloanal anastomosis).
III. To make preliminary observations of patient survival and patterns of recurrence for
this treatment combination.
IV. To evaluate anastomotic and sphincter function following pre-op combined modality
therapy.
OUTLINE: This is a dose-escalation study of preoperative oxaliplatin.
Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks.
Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.
Cohorts of 5 patients each receive escalating doses of oxaliplatin until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which
at least 2 of 5 patients experience dose-limiting toxicity. Additional patients are treated
at the MTD.
Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and
radiotherapy. The surgical procedure is determined by the extent of the tumor before
preoperative therapy. The type of operative procedure may be abdominoperineal resection, low
anterior resection (LAR), or LAR/coloanal anastomosis.
Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin
calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses.
Patients are followed every 3 months for 2.5 years, every 6 months for 3 years, then
annually for 5 years.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Completed |
NCT03871959 -
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
|
Phase 1 | |
Recruiting |
NCT05080673 -
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
|
N/A | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Recruiting |
NCT03303547 -
Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits
|
N/A | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT04005118 -
Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
|
||
Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
Completed |
NCT00307736 -
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00303628 -
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
|
Phase 3 | |
Terminated |
NCT02425683 -
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01340755 -
Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
|
N/A |